Quarterly ResultMay 5, 2026, 07:53 AM
Rhythm Pharma Q1 Revenue $60.1M; IMCIVREE U.S. launch strong
AI Summary
Rhythm Pharmaceuticals reported Q1 2026 financial results, with net product revenue of $60.1 million, a 59.4% increase year-over-year. The company announced a strong U.S. launch for IMCIVREE in acquired hypothalamic obesity, receiving over 150 patient start forms in six weeks. European Commission marketing authorization for IMCIVREE in acquired HO was granted, with Japanese regulatory review underway. Despite a net loss of $(56.7) million, the company maintains a strong cash position, expecting to fund operations for at least 24 months.
Key Highlights
- IMCIVREE U.S. launch for acquired HO received over 150 patient start forms in 6 weeks.
- Q1 2026 net product revenue was $60.1 million, up 59.4% YoY.
- U.S. revenue was $36.9 million; ex-U.S. revenue was $23.2 million, up 27% sequentially.
- Q1 2026 net loss was $(56.7) million, or $(0.83) per share.
- Cash, cash equivalents, and short-term investments totaled $340.6 million.
- European Commission granted IMCIVREE Marketing Authorization for acquired HO.
- Japanese regulatory review for setmelanotide in acquired HO is underway.
- Anticipates $385M-$415M in Non-GAAP Operating Expenses for 2026.